Mereo BioPharma (MREO) Return on Capital Employed (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Return on Capital Employed data on file, last reported at 101.57% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 101.57%, down 11631.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 101.57% (down 11631.0% YoY), and the FY2025 annual result was 70.55%, down 8941.0% from the prior year.
• Return on Capital Employed retreated to 101.57% in Q1 2026 per MREO's latest filing, from 88.23% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 21.57% in Q3 2025 and troughed at 101.57% in Q1 2026.
• A 4-year average of 32.28% and a median of 43.9% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed surged 8475 bps in 2025, then tumbled 11631 bps in 2026.
• A 4-year view of Return on Capital Employed shows it stood at 37.68% in 2023, then soared by 142 bps to 15.81% in 2024, then tumbled by 658 bps to 88.23% in 2025, then declined by 15 bps to 101.57% in 2026.
• Business Quant data shows MREO's Return on Capital Employed at 101.57% in Q1 2026, 88.23% in Q4 2025, and 21.57% in Q3 2025.